Quote | Mereo BioPharma Group (NASDAQ:MREO)
Last: | $3.285 |
---|---|
Change Percent: | 9.5% |
Open: | $3.1 |
Close: | $3 |
High: | $3.45 |
Low: | $3.05 |
Volume: | 1,544,035 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Mereo BioPharma Group (NASDAQ:MREO)
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...
2024-03-27 16:49:28 ET More on Mereo BioPharma Group Mereo BioPharma provides update on pipeline progress, reaffirms cash runway guidance Seeking Alpha’s Quant Rating on Mereo BioPharma Group Historical earnings data for Mereo BioPharma Group Financial...
Message Board Posts | Mereo BioPharma Group (NASDAQ:MREO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $MREO News Article - Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual | whytestocks | investorshangout | 04/13/2023 12:05:47 PM |
znewcar1: $MREO 34% v2,5M C.75 f124,985M H.7734 ML.4945 YL.51 | znewcar1 | investorshangout | 12/30/2022 9:41:53 PM |
whytestocks: $MREO News Article - Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capita | whytestocks | investorshangout | 09/26/2022 2:40:59 PM |
znewcar1: MREO 30% v53M C1.69 f117M H1.85 | znewcar1 | investorshangout | 06/21/2022 9:15:25 PM |
whytestocks: $MREO News Article - Mereo BioPharma to Participate in a Fireside Chat at the 10th Annu | whytestocks | investorshangout | 02/18/2021 1:15:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partn...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...